Navigation Links
Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
Date:12/14/2010

or the treatment of other cancers, building on the broad potential of GITR as a fundamental mechanism involved in cancer as well as preclinical proof of concept studies of TRX518 in multiple models of established and metastatic cancer.

"Starting this first-in-human study with TRX518 in an oncology indication is an important milestone for Tolerx. TRX518 has a novel mechanism of action and has the potential to enhance an anti-tumor immune response, regardless of tumor type, and this has tremendous potential for a broad variety of malignancies," said Louis Vaickus, MD, Chief Medical Officer at Tolerx.  "TRX518 works through GITR (glucocorticoid-induced tumor necrosis factor receptor), a molecule that has been recognized by the National Cancer Institute and other experts as one of the most promising targets in cancer immunotherapy."

About TRX518

TRX518 is a targeted T cell immunotherapy that activates GITR (glucocorticoid-induced tumor necrosis factor receptor) found on multiple types of T cells and other immune cells. Activated GITR plays a role in directing the anti-tumor immune response via activating tumor-antigen-specific T effector cells, as well as abrogating the suppression induced by inappropriately activated T regulatory cells.  In preclinical studies, TRX518 achieved its targeted effect without compromising normal immune function, and preclinical models suggest TRX518 may have a reduced risk of causing serious inflammatory side effects that can result from cytokine release.  TRX518 is designed to have activating and sustaining effects on T cells for enhancing the immune system's responses against cancer cells, including responses that may occur with TRX518 alone, as well as complementary responses in combination with other cancer therapies including vaccines.  

About Tolerx

Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress
2. Tolerx Announces Amendment to Phase 3 DEFEND Protocol
3. Tolerx Expands Phase 3 DEFEND Trial of Otelixizumab in Europe
4. Laureate Announces Manufacturing Agreement with Tolerx
5. Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
6. GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
7. SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK
8. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
9. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
10. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
11. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... LANSING, Mich. , March 27, 2015  Neogen ... Properties, LLC, has adopted a prearranged trading plan in ... James Herbert , Chairman and CEO of Neogen Corporation, ... shares of Neogen Corporation common stock. Herbert ... the disclosure was appropriate. The filing is only for ...
(Date:3/27/2015)... ROCKVILLE, Md. , March 27, 2015  CASI ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a commercial focus on ... the three and 12 months ended December 31, 2014.  ... of ($1.6 million), or ($0.05) per share, for the ...
(Date:3/26/2015)... The Market Element LLC, a leading inbound ... Designing Gig LLC to provide website design, development, and ... this alliance with Designing Gig represents a pivotal moment ... comprehensive, end-to-end, digital solution for our clients, which now ... Miller, president of The Market Element. “For small and ...
(Date:3/26/2015)... March 26, 2015 ReliantHeart, Inc., an ... Transonic, a supplier of precision transit-time flow measurement solutions, ... greatly improve the efficiency of the HeartAssist5® ... patients to experience greater mobility and peace of mind. ... miniature flow board, will draw 1/6th of the power ...
Breaking Biology Technology:Neogen CEO adopts 10b5-1 Trading Plan 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... measures urinary 11dhTxB2 to assess aspirin effectDENVER, March ... CONX), a worldwide developer and marketer of diagnostic ... its AspirinWorks(R) Test March 29 - 31 at ... Scientific Session. The annual meeting will take place ...
... regulatory hiccups, the number of biosimilars in the ... patent expiry of key biopharmaceuticals has opened up ... of biosimilars. In addition, payers, perception of biosimilars, ... their safety, efficacy and affordability, will further bolster ...
... 18 , - ... and Compliance Challenges of Radiologic Technologists, Managers , ... Mosby,s Imaging Suite,( http://www.mosbysimagingsuite.com ), the first fully ... education, communication and,compliance challenges of radiologic technologists and ...
Cached Biology Technology:Corgenix to Exhibit AspirinWorks(R) Test at ACC.09 2Corgenix to Exhibit AspirinWorks(R) Test at ACC.09 3The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan 2The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan 3The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan 4New Online Imaging Suite Boosts Healthcare Imaging Efficiency, Productivity, and Revenues 2New Online Imaging Suite Boosts Healthcare Imaging Efficiency, Productivity, and Revenues 3New Online Imaging Suite Boosts Healthcare Imaging Efficiency, Productivity, and Revenues 4
(Date:3/10/2015)... , March 10, 2015  NXT-ID, Inc. (NASDAQ: ... the "Company"), a biometric authentication company focused on ... Wocket™ smart wallet has been named the "Number ... Modern. Rethink Modern ( http://www.rethinkmodern.com/ ) ... for your home and lifestyle that have a unique ...
(Date:3/3/2015)... Calif. , March 3, 2015 /PRNewswire/ ... leading provider of advanced cryogenic logistics solutions ... including immunotherapies, stem cells, cell lines, clinical ... reproductive medicine, today announced the expansion of ... Research Centers, ("Fred Hutch") Clinical Research ...
(Date:3/2/2015)...   Neurotechnology , a provider of high-precision biometric, ... Software Development Kit (SDK). The SentiGaze algorithm enables ... webcams to track eye movements and generate heatmaps based ... can be used for applications such as analysis of ... SDK can also be used to develop interfaces for ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... --- How do the French get away with a clean ... fats? Scientists have long suspected that the answer to the ... of a new study bring them closer to understanding why. ... Public Library of Science (PLoS) ONE, researchers from industry and ...
... York next week to discuss new approaches to one ... weather. Five years ago, Professor Peter Bernath, of ... the Atmospheric Chemistry Experiment (ACE) satellite mission. To ... University at the King,s Manor in York will review ...
... release is available in German . ... cormorants in order to reconcile nature conservation and fishing ... work at the European level, researchers from the Helmholtz ... journal Environmental Conservation. Furthermore, they suggest a five-step action ...
Cached Biology News:Substance in red wine found to keep hearts young 2Substance in red wine found to keep hearts young 3York symposium puts focus on chemical 'weather' 2The cormorant -- the 'black plague' or an example of successful species conservation? 2The cormorant -- the 'black plague' or an example of successful species conservation? 3The cormorant -- the 'black plague' or an example of successful species conservation? 4The cormorant -- the 'black plague' or an example of successful species conservation? 5
Cytofix/Cytoperm Plus Kit with GolgiPlug 250 Tests...
Complete PCR kit. Includes: MasterAmp™ Taq DNA Polymerase, 10X PCR Buffer, MasterAmp™ 10X PCR Enhancer, dNTP Mix, 2.5 mM each, 25 mM MgCl2, Enzyme Dilution Buffer, Control Template and Prim...
Mouse monoclonal to OCIL ( Abpromise for all tested applications)....
Oxidative Stress-Inducible Protein Tyrosine Phosphatase...
Biology Products: